Home >> Research Area >>Apoptosis>>MDM2>> YH239-EE

YH239-EE

p53-MDM2 antagonist, potent CAS# 1364488-67-4

YH239-EE

Catalog No. BCC5454----Order now to get a substantial discount!

Product Name & Size Price Stock
YH239-EE: 5mg $46 In Stock
YH239-EE: 10mg Please Inquire In Stock
YH239-EE: 20mg Please Inquire Please Inquire
YH239-EE: 50mg Please Inquire Please Inquire
YH239-EE: 100mg Please Inquire Please Inquire
YH239-EE: 200mg Please Inquire Please Inquire
YH239-EE: 500mg Please Inquire Please Inquire
YH239-EE: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of YH239-EE

Number of papers citing our products

Chemical structure

YH239-EE

3D structure

Chemical Properties of YH239-EE

Cas No. 1364488-67-4 SDF Download SDF
PubChem ID 56943013 Appearance Powder
Formula C25H27Cl2N3O4 M.Wt 504.41
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 55 mg/mL (109.04 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name ethyl 3-[2-(tert-butylamino)-1-[(4-chlorophenyl)methyl-formylamino]-2-oxoethyl]-6-chloro-1H-indole-2-carboxylate
SMILES CCOC(=O)C1=C(C2=C(N1)C=C(C=C2)Cl)C(C(=O)NC(C)(C)C)N(CC3=CC=C(C=C3)Cl)C=O
Standard InChIKey OTUBDDRFPQLPKD-UHFFFAOYSA-N
Standard InChI InChI=1S/C25H27Cl2N3O4/c1-5-34-24(33)21-20(18-11-10-17(27)12-19(18)28-21)22(23(32)29-25(2,3)4)30(14-31)13-15-6-8-16(26)9-7-15/h6-12,14,22,28H,5,13H2,1-4H3,(H,29,32)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of YH239-EE

DescriptionYH239-EE is a potent antagonist of p53-MDM2 and an inducer of apoptosis.
Targetsp53-MDM2    

YH239-EE Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

YH239-EE Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of YH239-EE

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.9825 mL 9.9126 mL 19.8251 mL 39.6503 mL 49.5629 mL
5 mM 0.3965 mL 1.9825 mL 3.965 mL 7.9301 mL 9.9126 mL
10 mM 0.1983 mL 0.9913 mL 1.9825 mL 3.965 mL 4.9563 mL
50 mM 0.0397 mL 0.1983 mL 0.3965 mL 0.793 mL 0.9913 mL
100 mM 0.0198 mL 0.0991 mL 0.1983 mL 0.3965 mL 0.4956 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on YH239-EE

YH239-EE is a potent antagonist of p53-MDM2 [1].

p53 is a transcription factor and functions as a tumor suppressor. MDM2 is a negative regulator of p53. The interaction of p53 and MDM2 has emerged as a novel target for anticancer drugs [1].

YH239-EE is a potent p53-MDM2 antagonist. In OCI-AML-3 cells, YH239-EE potently inhibited cell proliferation. In AML cell lines, YH239-EE induced a cell cycle arrest and cell accumulation in the sub-G1 phase. YH239-EE induced apoptosis by 11.8-fold, 5.6-fold and 13.1-fold in OCI-AML-3, MOLM-13 and NB4 AML cell lines, respectively. In MOLM-13 cells, YH239 exhibited almost no apoptotic effect. However, YH239-EE significantly induced apoptosis. In MOLM-13 cells, (+)-YH239-EE and (−)-YH239-EE inhibited metabolic activity with EC50 values of 7.5 μM and 25.2 μM and induced apoptosis with 13.7% and 51.5% viable cells, respectively. (+)-YH239-EE (20 μM) induced p53 and significantly activated caspase 3 and 7 [1].

Reference:
[1].  Huang Y, Wolf S, Beck B, et al. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. ACS Chem Biol, 2014, 9(3): 802-811.

Featured Products
New Products
 

References on YH239-EE

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.[Pubmed:24405416]

ACS Chem Biol. 2014 Mar 21;9(3):802-11.

The inhibition of p53-MDM2 interaction is a promising new approach to non-genotoxic cancer treatment. A potential application for drugs blocking the p53-MDM2 interaction is acute myeloid leukemia (AML) due to the occurrence of wild type p53 (wt p53) in the majority of patients. Although there are very promising preclinical results of several p53-MDM2 antagonists in early development, none of the compounds have yet proven the utility as a next generation anticancer agent. Herein we report the design, synthesis and optimization of YH239-EE (ethyl ester of the free carboxylic acid compound YH239), a potent p53-MDM2 antagonizing and apoptosis-inducing agent characterized by a number of leukemia cell lines as well as patient-derived AML blast samples. The structural basis of the interaction between MDM2 (the p53 receptor) and YH239 is elucidated by a co-crystal structure. YH239-EE acts as a prodrug and is the most potent compound that induces apoptosis in AML cells and patient samples. The observed superior activity compared to reference compounds provides the preclinical basis for further investigation and progression of YH239-EE.

Description

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent.

Keywords:

YH239-EE,1364488-67-4,Natural Products,MDM2, buy YH239-EE , YH239-EE supplier , purchase YH239-EE , YH239-EE cost , YH239-EE manufacturer , order YH239-EE , high purity YH239-EE

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: